Report cover image

Global Inactivated Vaccine Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Jul 16, 2025
Length 199 Pages
SKU # APRC20280348

Description

Summary

According to APO Research, the global Inactivated Vaccine market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Inactivated Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.

The Asia-Pacific market for Inactivated Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Inactivated Vaccine market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.

The Europe market for Inactivated Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Inactivated Vaccine market include Johnson & Johnson(U.S.), Merck & Co(U.S.), Pfizer(U.S.), GlaxoSmithKline(U.K.), Serum Institute of India Pvt(India), Sanofi Pasteur(France), MedImmune(U.S.), Emergent BioSolutions(U.S.) and CSL Limited(Australia), etc. In 2024, the top three vendors accounted for approximately % of the market revenue.

This report presents an overview of global market for Inactivated Vaccine, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Inactivated Vaccine, also provides the value of main regions and countries. Of the upcoming market potential for Inactivated Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Inactivated Vaccine revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global Inactivated Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Inactivated Vaccine company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Inactivated Vaccine Segment by Company

Johnson & Johnson(U.S.)
Merck & Co(U.S.)
Pfizer(U.S.)
GlaxoSmithKline(U.K.)
Serum Institute of India Pvt(India)
Sanofi Pasteur(France)
MedImmune(U.S.)
Emergent BioSolutions(U.S.)
CSL Limited(Australia)
Astellas Pharma(Japan)
Inactivated Vaccine Segment by Type

Children Inactivated Vaccine
Adult Inactivated Vaccine
Inactivated Vaccine Segment by Application

Hospital
Medical Center
Inactivated Vaccine Segment by Region

North America

United States
Canada
Europe

Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific

China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America

Mexico
Brazil
Argentina
Middle East & Africa

Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Inactivated Vaccine status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Inactivated Vaccine key companies, revenue, market share, and recent developments.
3. To split the Inactivated Vaccine breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Inactivated Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Inactivated Vaccine significant trends, drivers, influence factors in global and regions.
6. To analyze Inactivated Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Inactivated Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Inactivated Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Inactivated Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Inactivated Vaccine industry.
Chapter 3: Detailed analysis of Inactivated Vaccine company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Inactivated Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Inactivated Vaccine in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

199 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Inactivated Vaccine Market Size, 2020 VS 2024 VS 2031
1.3 Global Inactivated Vaccine Market Size (2020-2031)
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Inactivated Vaccine Market Dynamics
2.1 Inactivated Vaccine Industry Trends
2.2 Inactivated Vaccine Industry Drivers
2.3 Inactivated Vaccine Industry Opportunities and Challenges
2.4 Inactivated Vaccine Industry Restraints
3 Inactivated Vaccine Market by Company
3.1 Global Inactivated Vaccine Company Revenue Ranking in 2024
3.2 Global Inactivated Vaccine Revenue by Company (2020-2025)
3.3 Global Inactivated Vaccine Company Ranking (2023-2025)
3.4 Global Inactivated Vaccine Company Manufacturing Base and Headquarters
3.5 Global Inactivated Vaccine Company Product Type and Application
3.6 Global Inactivated Vaccine Company Establishment Date
3.7 Market Competitive Analysis
3.7.1 Global Inactivated Vaccine Market Concentration Ratio (CR5 and HHI)
3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.7.3 2024 Inactivated Vaccine Tier 1, Tier 2, and Tier 3 Companies
3.8 Mergers and Acquisitions Expansion
4 Inactivated Vaccine Market by Type
4.1 Inactivated Vaccine Type Introduction
4.1.1 Children Inactivated Vaccine
4.1.2 Adult Inactivated Vaccine
4.2 Global Inactivated Vaccine Sales Value by Type
4.2.1 Global Inactivated Vaccine Sales Value by Type (2020 VS 2024 VS 2031)
4.2.2 Global Inactivated Vaccine Sales Value by Type (2020-2031)
4.2.3 Global Inactivated Vaccine Sales Value Share by Type (2020-2031)
5 Inactivated Vaccine Market by Application
5.1 Inactivated Vaccine Application Introduction
5.1.1 Hospital
5.1.2 Medical Center
5.2 Global Inactivated Vaccine Sales Value by Application
5.2.1 Global Inactivated Vaccine Sales Value by Application (2020 VS 2024 VS 2031)
5.2.2 Global Inactivated Vaccine Sales Value by Application (2020-2031)
5.2.3 Global Inactivated Vaccine Sales Value Share by Application (2020-2031)
6 Inactivated Vaccine Regional Value Analysis
6.1 Global Inactivated Vaccine Sales Value by Region: 2020 VS 2024 VS 2031
6.2 Global Inactivated Vaccine Sales Value by Region (2020-2031)
6.2.1 Global Inactivated Vaccine Sales Value by Region: 2020-2025
6.2.2 Global Inactivated Vaccine Sales Value by Region (2026-2031)
6.3 North America
6.3.1 North America Inactivated Vaccine Sales Value (2020-2031)
6.3.2 North America Inactivated Vaccine Sales Value Share by Country, 2024 VS 2031
6.4 Europe
6.4.1 Europe Inactivated Vaccine Sales Value (2020-2031)
6.4.2 Europe Inactivated Vaccine Sales Value Share by Country, 2024 VS 2031
6.5 Asia-Pacific
6.5.1 Asia-Pacific Inactivated Vaccine Sales Value (2020-2031)
6.5.2 Asia-Pacific Inactivated Vaccine Sales Value Share by Country, 2024 VS 2031
6.6 South America
6.6.1 South America Inactivated Vaccine Sales Value (2020-2031)
6.6.2 South America Inactivated Vaccine Sales Value Share by Country, 2024 VS 2031
6.7 Middle East & Africa
6.7.1 Middle East & Africa Inactivated Vaccine Sales Value (2020-2031)
6.7.2 Middle East & Africa Inactivated Vaccine Sales Value Share by Country, 2024 VS 2031
7 Inactivated Vaccine Country-level Value Analysis
7.1 Global Inactivated Vaccine Sales Value by Country: 2020 VS 2024 VS 2031
7.2 Global Inactivated Vaccine Sales Value by Country (2020-2031)
7.2.1 Global Inactivated Vaccine Sales Value by Country (2020-2025)
7.2.2 Global Inactivated Vaccine Sales Value by Country (2026-2031)
7.3 USA
7.3.1 USA Inactivated Vaccine Sales Value Growth Rate (2020-2031)
7.3.2 USA Inactivated Vaccine Sales Value Share by Type, 2024 VS 2031
7.3.3 USA Inactivated Vaccine Sales Value Share by Application, 2024 VS 2031
7.4 Canada
7.4.1 Canada Inactivated Vaccine Sales Value Growth Rate (2020-2031)
7.4.2 Canada Inactivated Vaccine Sales Value Share by Type, 2024 VS 2031
7.4.3 Canada Inactivated Vaccine Sales Value Share by Application, 2024 VS 2031
7.5 Mexico
7.5.1 Mexico Inactivated Vaccine Sales Value Growth Rate (2020-2031)
7.5.2 Mexico Inactivated Vaccine Sales Value Share by Type, 2024 VS 2031
7.5.3 Mexico Inactivated Vaccine Sales Value Share by Application, 2024 VS 2031
7.6 Germany
7.6.1 Germany Inactivated Vaccine Sales Value Growth Rate (2020-2031)
7.6.2 Germany Inactivated Vaccine Sales Value Share by Type, 2024 VS 2031
7.6.3 Germany Inactivated Vaccine Sales Value Share by Application, 2024 VS 2031
7.7 France
7.7.1 France Inactivated Vaccine Sales Value Growth Rate (2020-2031)
7.7.2 France Inactivated Vaccine Sales Value Share by Type, 2024 VS 2031
7.7.3 France Inactivated Vaccine Sales Value Share by Application, 2024 VS 2031
7.8 U.K.
7.8.1 U.K. Inactivated Vaccine Sales Value Growth Rate (2020-2031)
7.8.2 U.K. Inactivated Vaccine Sales Value Share by Type, 2024 VS 2031
7.8.3 U.K. Inactivated Vaccine Sales Value Share by Application, 2024 VS 2031
7.9 Italy
7.9.1 Italy Inactivated Vaccine Sales Value Growth Rate (2020-2031)
7.9.2 Italy Inactivated Vaccine Sales Value Share by Type, 2024 VS 2031
7.9.3 Italy Inactivated Vaccine Sales Value Share by Application, 2024 VS 2031
7.10 Spain
7.10.1 Spain Inactivated Vaccine Sales Value Growth Rate (2020-2031)
7.10.2 Spain Inactivated Vaccine Sales Value Share by Type, 2024 VS 2031
7.10.3 Spain Inactivated Vaccine Sales Value Share by Application, 2024 VS 2031
7.11 Russia
7.11.1 Russia Inactivated Vaccine Sales Value Growth Rate (2020-2031)
7.11.2 Russia Inactivated Vaccine Sales Value Share by Type, 2024 VS 2031
7.11.3 Russia Inactivated Vaccine Sales Value Share by Application, 2024 VS 2031
7.12 Netherlands
7.12.1 Netherlands Inactivated Vaccine Sales Value Growth Rate (2020-2031)
7.12.2 Netherlands Inactivated Vaccine Sales Value Share by Type, 2024 VS 2031
7.12.3 Netherlands Inactivated Vaccine Sales Value Share by Application, 2024 VS 2031
7.13 Nordic Countries
7.13.1 Nordic Countries Inactivated Vaccine Sales Value Growth Rate (2020-2031)
7.13.2 Nordic Countries Inactivated Vaccine Sales Value Share by Type, 2024 VS 2031
7.13.3 Nordic Countries Inactivated Vaccine Sales Value Share by Application, 2024 VS 2031
7.14 China
7.14.1 China Inactivated Vaccine Sales Value Growth Rate (2020-2031)
7.14.2 China Inactivated Vaccine Sales Value Share by Type, 2024 VS 2031
7.14.3 China Inactivated Vaccine Sales Value Share by Application, 2024 VS 2031
7.15 Japan
7.15.1 Japan Inactivated Vaccine Sales Value Growth Rate (2020-2031)
7.15.2 Japan Inactivated Vaccine Sales Value Share by Type, 2024 VS 2031
7.15.3 Japan Inactivated Vaccine Sales Value Share by Application, 2024 VS 2031
7.16 South Korea
7.16.1 South Korea Inactivated Vaccine Sales Value Growth Rate (2020-2031)
7.16.2 South Korea Inactivated Vaccine Sales Value Share by Type, 2024 VS 2031
7.16.3 South Korea Inactivated Vaccine Sales Value Share by Application, 2024 VS 2031
7.17 India
7.17.1 India Inactivated Vaccine Sales Value Growth Rate (2020-2031)
7.17.2 India Inactivated Vaccine Sales Value Share by Type, 2024 VS 2031
7.17.3 India Inactivated Vaccine Sales Value Share by Application, 2024 VS 2031
7.18 Australia
7.18.1 Australia Inactivated Vaccine Sales Value Growth Rate (2020-2031)
7.18.2 Australia Inactivated Vaccine Sales Value Share by Type, 2024 VS 2031
7.18.3 Australia Inactivated Vaccine Sales Value Share by Application, 2024 VS 2031
7.19 Southeast Asia
7.19.1 Southeast Asia Inactivated Vaccine Sales Value Growth Rate (2020-2031)
7.19.2 Southeast Asia Inactivated Vaccine Sales Value Share by Type, 2024 VS 2031
7.19.3 Southeast Asia Inactivated Vaccine Sales Value Share by Application, 2024 VS 2031
7.20 Brazil
7.20.1 Brazil Inactivated Vaccine Sales Value Growth Rate (2020-2031)
7.20.2 Brazil Inactivated Vaccine Sales Value Share by Type, 2024 VS 2031
7.20.3 Brazil Inactivated Vaccine Sales Value Share by Application, 2024 VS 2031
7.21 Argentina
7.21.1 Argentina Inactivated Vaccine Sales Value Growth Rate (2020-2031)
7.21.2 Argentina Inactivated Vaccine Sales Value Share by Type, 2024 VS 2031
7.21.3 Argentina Inactivated Vaccine Sales Value Share by Application, 2024 VS 2031
7.22 Chile
7.22.1 Chile Inactivated Vaccine Sales Value Growth Rate (2020-2031)
7.22.2 Chile Inactivated Vaccine Sales Value Share by Type, 2024 VS 2031
7.22.3 Chile Inactivated Vaccine Sales Value Share by Application, 2024 VS 2031
7.23 Colombia
7.23.1 Colombia Inactivated Vaccine Sales Value Growth Rate (2020-2031)
7.23.2 Colombia Inactivated Vaccine Sales Value Share by Type, 2024 VS 2031
7.23.3 Colombia Inactivated Vaccine Sales Value Share by Application, 2024 VS 2031
7.24 Peru
7.24.1 Peru Inactivated Vaccine Sales Value Growth Rate (2020-2031)
7.24.2 Peru Inactivated Vaccine Sales Value Share by Type, 2024 VS 2031
7.24.3 Peru Inactivated Vaccine Sales Value Share by Application, 2024 VS 2031
7.25 Saudi Arabia
7.25.1 Saudi Arabia Inactivated Vaccine Sales Value Growth Rate (2020-2031)
7.25.2 Saudi Arabia Inactivated Vaccine Sales Value Share by Type, 2024 VS 2031
7.25.3 Saudi Arabia Inactivated Vaccine Sales Value Share by Application, 2024 VS 2031
7.26 Israel
7.26.1 Israel Inactivated Vaccine Sales Value Growth Rate (2020-2031)
7.26.2 Israel Inactivated Vaccine Sales Value Share by Type, 2024 VS 2031
7.26.3 Israel Inactivated Vaccine Sales Value Share by Application, 2024 VS 2031
7.27 UAE
7.27.1 UAE Inactivated Vaccine Sales Value Growth Rate (2020-2031)
7.27.2 UAE Inactivated Vaccine Sales Value Share by Type, 2024 VS 2031
7.27.3 UAE Inactivated Vaccine Sales Value Share by Application, 2024 VS 2031
7.28 Turkey
7.28.1 Turkey Inactivated Vaccine Sales Value Growth Rate (2020-2031)
7.28.2 Turkey Inactivated Vaccine Sales Value Share by Type, 2024 VS 2031
7.28.3 Turkey Inactivated Vaccine Sales Value Share by Application, 2024 VS 2031
7.29 Iran
7.29.1 Iran Inactivated Vaccine Sales Value Growth Rate (2020-2031)
7.29.2 Iran Inactivated Vaccine Sales Value Share by Type, 2024 VS 2031
7.29.3 Iran Inactivated Vaccine Sales Value Share by Application, 2024 VS 2031
7.30 Egypt
7.30.1 Egypt Inactivated Vaccine Sales Value Growth Rate (2020-2031)
7.30.2 Egypt Inactivated Vaccine Sales Value Share by Type, 2024 VS 2031
7.30.3 Egypt Inactivated Vaccine Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Johnson & Johnson(U.S.)
8.1.1 Johnson & Johnson(U.S.) Comapny Information
8.1.2 Johnson & Johnson(U.S.) Business Overview
8.1.3 Johnson & Johnson(U.S.) Inactivated Vaccine Revenue and Gross Margin (2020-2025)
8.1.4 Johnson & Johnson(U.S.) Inactivated Vaccine Product Portfolio
8.1.5 Johnson & Johnson(U.S.) Recent Developments
8.2 Merck & Co(U.S.)
8.2.1 Merck & Co(U.S.) Comapny Information
8.2.2 Merck & Co(U.S.) Business Overview
8.2.3 Merck & Co(U.S.) Inactivated Vaccine Revenue and Gross Margin (2020-2025)
8.2.4 Merck & Co(U.S.) Inactivated Vaccine Product Portfolio
8.2.5 Merck & Co(U.S.) Recent Developments
8.3 Pfizer(U.S.)
8.3.1 Pfizer(U.S.) Comapny Information
8.3.2 Pfizer(U.S.) Business Overview
8.3.3 Pfizer(U.S.) Inactivated Vaccine Revenue and Gross Margin (2020-2025)
8.3.4 Pfizer(U.S.) Inactivated Vaccine Product Portfolio
8.3.5 Pfizer(U.S.) Recent Developments
8.4 GlaxoSmithKline(U.K.)
8.4.1 GlaxoSmithKline(U.K.) Comapny Information
8.4.2 GlaxoSmithKline(U.K.) Business Overview
8.4.3 GlaxoSmithKline(U.K.) Inactivated Vaccine Revenue and Gross Margin (2020-2025)
8.4.4 GlaxoSmithKline(U.K.) Inactivated Vaccine Product Portfolio
8.4.5 GlaxoSmithKline(U.K.) Recent Developments
8.5 Serum Institute of India Pvt(India)
8.5.1 Serum Institute of India Pvt(India) Comapny Information
8.5.2 Serum Institute of India Pvt(India) Business Overview
8.5.3 Serum Institute of India Pvt(India) Inactivated Vaccine Revenue and Gross Margin (2020-2025)
8.5.4 Serum Institute of India Pvt(India) Inactivated Vaccine Product Portfolio
8.5.5 Serum Institute of India Pvt(India) Recent Developments
8.6 Sanofi Pasteur(France)
8.6.1 Sanofi Pasteur(France) Comapny Information
8.6.2 Sanofi Pasteur(France) Business Overview
8.6.3 Sanofi Pasteur(France) Inactivated Vaccine Revenue and Gross Margin (2020-2025)
8.6.4 Sanofi Pasteur(France) Inactivated Vaccine Product Portfolio
8.6.5 Sanofi Pasteur(France) Recent Developments
8.7 MedImmune(U.S.)
8.7.1 MedImmune(U.S.) Comapny Information
8.7.2 MedImmune(U.S.) Business Overview
8.7.3 MedImmune(U.S.) Inactivated Vaccine Revenue and Gross Margin (2020-2025)
8.7.4 MedImmune(U.S.) Inactivated Vaccine Product Portfolio
8.7.5 MedImmune(U.S.) Recent Developments
8.8 Emergent BioSolutions(U.S.)
8.8.1 Emergent BioSolutions(U.S.) Comapny Information
8.8.2 Emergent BioSolutions(U.S.) Business Overview
8.8.3 Emergent BioSolutions(U.S.) Inactivated Vaccine Revenue and Gross Margin (2020-2025)
8.8.4 Emergent BioSolutions(U.S.) Inactivated Vaccine Product Portfolio
8.8.5 Emergent BioSolutions(U.S.) Recent Developments
8.9 CSL Limited(Australia)
8.9.1 CSL Limited(Australia) Comapny Information
8.9.2 CSL Limited(Australia) Business Overview
8.9.3 CSL Limited(Australia) Inactivated Vaccine Revenue and Gross Margin (2020-2025)
8.9.4 CSL Limited(Australia) Inactivated Vaccine Product Portfolio
8.9.5 CSL Limited(Australia) Recent Developments
8.10 Astellas Pharma(Japan)
8.10.1 Astellas Pharma(Japan) Comapny Information
8.10.2 Astellas Pharma(Japan) Business Overview
8.10.3 Astellas Pharma(Japan) Inactivated Vaccine Revenue and Gross Margin (2020-2025)
8.10.4 Astellas Pharma(Japan) Inactivated Vaccine Product Portfolio
8.10.5 Astellas Pharma(Japan) Recent Developments
9 Concluding Insights
10 Appendix
10.1 Reasons for Doing This Study
10.2 Research Methodology
10.3 Research Process
10.4 Authors List of This Report
10.5 Data Source
10.5.1 Secondary Sources
10.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.